{"id":"bevacizumab-folfiri-3","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Proteinuria"},{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1201583","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bevacizumab is a monoclonal antibody that binds vascular endothelial growth factor (VEGF), preventing new blood vessel formation that tumors depend on for growth and metastasis. FOLFIRI-3 is a combination chemotherapy regimen where fluorouracil and leucovorin inhibit thymidylate synthase, and irinotecan inhibits topoisomerase I, together inducing apoptosis in rapidly dividing cancer cells. The combination leverages anti-angiogenic and cytotoxic mechanisms for enhanced efficacy.","oneSentence":"Bevacizumab blocks VEGF to inhibit tumor angiogenesis, while FOLFIRI-3 (fluorouracil, leucovorin, and irinotecan) provides chemotherapy-induced DNA damage and cell death.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:04.451Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer (Phase 3 pipeline indication)"}]},"trialDetails":[{"nctId":"NCT03288987","phase":"PHASE3","title":"Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"AryoGen Pharmed Co.","startDate":"2016-10-04","conditions":"Metastatic Colorectal Cancer","enrollment":126},{"nctId":"NCT01375816","phase":"PHASE2","title":"Liposome-encapsulated Irinotecan Hydrochloride PEP02 or Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil as Second-Line Therapy in Treating Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2011-05","conditions":"Colorectal Cancer","enrollment":55},{"nctId":"NCT00544011","phase":"PHASE2","title":"Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Hopital Jean Minjoz","startDate":"2007-04","conditions":"Colorectal Cancer","enrollment":47}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["FOLFIRI-3 = irinotecan + calcium folinate + 5-fluorouracil"],"phase":"phase_3","status":"active","brandName":"Bevacizumab + FOLFIRI-3","genericName":"Bevacizumab + FOLFIRI-3","companyName":"AryoGen Pharmed Co.","companyId":"aryogen-pharmed-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bevacizumab blocks VEGF to inhibit tumor angiogenesis, while FOLFIRI-3 (fluorouracil, leucovorin, and irinotecan) provides chemotherapy-induced DNA damage and cell death. Used for Metastatic colorectal cancer (Phase 3 pipeline indication).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}